Professor David Andrew Bradley is Professor Emeritus at the University of Surrey, UK, with more than 47 years of academic experience, including 14 years as Director of the MSc Medical Physics programs at both the University of Exeter and the University of Surrey. He has served as Secretary of the International Radiation Physics Society (IRPS) and as Editor-in-Chief of the British Journal of Radiology, Applied Radiation and Isotopes, and Radiation Physics and Chemistry, and currently continues his editorial contributions as Consulting Editor for the latter two journals. His extensive research spans radiation physics fundamentals and their applications in biomedicine, industry, and radiation safety. His work covers radioanalysis, radiological risks from Naturally Occurring Radioactive Material (NORM), tissue-characterization techniques, radiation effects on cells and tissues, and the development of luminescence dosimeters. His interest in dosimetry innovation led to the establishment of two companies—TrueInvivo Ltd. in the UK and Lumisyns Sdn Bhd in Malaysia.
Professor David Andrew Bradley is Professor Emeritus at the University of Surrey, UK, with more than 47 years of academic experience, including 14 years as Director of the MSc Medical Physics programs at both the University of Exeter and the University of Surrey. He has served as Secretary of the International Radiation Physics Society (IRPS) and as Editor-in-Chief of the British Journal of Radiology, Applied Radiation and Isotopes, and Radiation Physics and Chemistry, and currently continues his editorial contributions as Consulting Editor for the latter two journals. His extensive research spans radiation physics fundamentals and their applications in biomedicine, industry, and radiation safety. His work covers radioanalysis, radiological risks from Naturally Occurring Radioactive Material (NORM), tissue-characterization techniques, radiation effects on cells and tissues, and the development of luminescence dosimeters. His interest in dosimetry innovation led to the establishment of two companies—TrueInvivo Ltd. in the UK and Lumisyns Sdn Bhd in Malaysia.